Emerging Companies

VaxNewMo: bioconjugating antibacterial vaccines

VaxNewMo is developing a bioengineered platform that could yield inexpensive glyconjugate vaccines that prevent bacterial infections, including those not yet covered by existing vaccines. Traditional chemical glycoconjugation is laborious and expensive, as it typically involves...

Deerfield propels Civetta with $53M series A

Deerfield-backed Civetta Therapeutics LLC is building a platform to systematically identify small molecules targeting β-propeller proteins, a molecular class that has seen little drug development activity despite its ubiquity in the human genome. “There has...

Morphiex’s antisense take on CD47 aims for more than eating

Morphiex is breaking from the CD47 pack by undercutting the target’s expression on both tumor and immune cells instead of just blocking tumors’ “don’t eat me” signals via SIRPA. The company believes its antisense approach...

Longwood launches Immunitas with $39M and single-cell genomics platform

With $39M series A, Immunitas is harnessing single-cell analysis to identify new immune targets for cancer. Immunitas Therapeutics emerged from stealth mode on Thursday with a $39 million series A round and a single-cell genomics...

ShapeTx: Shaping up RNA editing

With its RNAfix platform, Shape is developing therapeutics that are designed to edit RNA in vivo by hijacking an enzyme in the target cell that naturally converts one RNA base to another. The company raised...

Cedilla: degrading proteins by modulating protein stability

While most protein degradation companies are developing bifunctional molecules that directly induce ubiquitin-mediated degradation, Cedilla is taking a different approach with monovalent small molecules that trigger a broader range of degradation mechanisms. “The concept of...

Mycovia tackling chronic infections with antifungal pipeline

Mycovia plans to bring a new generation of antifungals against CYP51 to market for difficult-to-treat indications, starting with chronic vaginal and nail infections. The company's lead product VT-1161 otesaconazole is in Phase III testing for...

Arkuda emerges from Atlas with genetic dementia program

Atlas-founded Arkuda is developing compounds for frontotemporal dementia due to genetic lysosomal deficits that could be applied to other neurodegenerative diseases linked to lysosomal dysfunction. Arkuda Therapeutics Inc. debuted Thursday with a $44 million series...

Ervaxx debuts with a new source of neoantigens

Ervaxx Ltd. emerged from stealth on Tuesday with £13 million ($16.8 million) from SV Health Investors and a platform for discovering and validating a new type of neoantigen present in the dark matter of the...

Tmunity: Manufacturing momentum for CAR and TCR therapies

Tmunity’s $75 million series B round will enable the company to keep advancing its CMC capabilities alongside its clinical and preclinical engineered CAR and TCR therapies for solid and blood tumors. Andreessen Horowitz (a16z) led...

Disc Medicine: Seeking Iron Balance via Hepcidin

Disc debuted Tuesday with a $50 million series A round and a pair of hepcidin modulators aimed at carving a place in hematological disorders, alongside a host of disease-modifying therapies that are much closer to...

Deep Genomics: Letting AI take the wheel

Deep Genomics announced its first candidate in September, pulling back the curtain on its holistic AI-enabled discovery platform that is designed to identify viable antisense oligonucleotide candidates faster than traditional discovery methods. CEO Brendan Frey...

Intrepida: Tackling the innate immune system to treat cancer

With a $9.5 million equity round, Intrepida aims to begin clinical testing by early 2021 of its first-in-class mAbs against BAG3, which can modulate the innate immune response to inhibit tumor growth in pancreatic cancer....

Verseau unveils tumor macrophage reprogramming strategy

Verseau is aiming to treat solid tumor patients who don't respond to T cell-targeting agents by reprogramming tumor-associated macrophages to make them immuno-stimulatory. Eight months after announcing a collaboration with 3SBio Inc. (HKSE:1530), Verseau Therapeutics...

Inscopix: scoping out better preclinical models via live brain imaging

With a platform to perform in vivo brain imaging, Inscopix Inc. is aiming to fix the poor predictive power of preclinical animal models for CNS diseases. Its advantage is the ability to use changes in...